We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Teligent Inc | NASDAQ:TLGT | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.1735 | 0.1721 | 0.1744 | 0 | 01:00:00 |
From May 2019 to May 2024
BUENA, N.J., July 9, 2015 /PRNewswire/ -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty generic pharmaceutical company, announced the Company will hold a conference call at 4:15 pm ET on Thursday, July 23, 2015 to discuss the 2nd quarter 2015 results.
The Company invites you to listen to the call by dialing 1-888-346-3479. International participants should call 1-412-902-4260. Canadian participants should call 1-855-669-9657. Participants should ask to be joined into the IGI Laboratories, Inc. call.
This call is being webcast by MultiVu (a PR Newswire Company) and can be accessed in the Investor Relations Section of IGI's website at www.igilabs.com.
About IGI Laboratories, Inc.
IGI Laboratories is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market.
Logo - http://photos.prnewswire.com/prnh/20130827/MM70487LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/igi-laboratories-to-hold-conference-call-for-2nd-quarter-2015-results-300110836.html
SOURCE IGI Laboratories, Inc.
Copyright 2015 PR Newswire
1 Year Teligent Chart |
1 Month Teligent Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
